Indaptus Therapeutics (INDP) trims executive salaries as director rescinds exit

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. reported changes to executive compensation and board composition. The company entered into salary adjustment agreements with Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, Ph.D. Effective January 15, 2026, each executive’s salary was set at $60,000 per year for the remainder of the year, paid according to the company’s standard payroll practices.

The company also disclosed that board member Anthony Maddaluna, who had previously notified the company of his intention to resign as of the next special meeting of stockholders, has rescinded that resignation. He will remain on the Board of Directors and continue to serve on the Compensation Committee and Nominating Committee.

false 0001857044 0001857044 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

January 20, 2026

Date of Report (Date of earliest event reported)

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40652		86-3158720
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3 Columbus Circle 15th Floor New York, New York		10019
(Address of principal executive offices)		(Zip Code)

(646) 427-2727

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		INDP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously reported on December 22, 2025, in connection with the transactions contemplated by the securities purchase agreement with investor David E. Lazar, Indaptus Therapeutics, Inc. (the “Company”) entered into employment modification agreements with, among others, Jeffrey A. Meckler, Co-Chief Executive Officer and Michael J. Newman, Ph.D., Chief Science Officer (collectively, the “Executive Officers”). On January 20, 2026, the Company further modified the employment agreements of each of the Executive Officers, pursuant to a salary adjustment agreement (the “Salary Adjustment Agreement”) in which, effective January 15, 2026, each of the Executive Officers’ salary was adjusted for the remainder of the year to $60,000 per annum in accordance with the Company’s standard payroll practice less applicable deductions.

The Salary Adjustment Agreement of each Mr. Meckler and Mr. Newman is attached hereto as Exhibit 10.1 and 10.2 and incorporated herein by reference.

Additionally, as previously disclosed in the Current Report on Form 8-K filed by the Company on January 2, 2026, Anthony Maddaluna, a member of the Company’s Board of Directors (the “Board”), notified the Company of his intention to resign from the Board effective as of the Company’s next special meeting of stockholders. On January 20, 2026, Mr. Maddaluna informed the Company that, after further consideration, he has decided to rescind his resignation and to remain as a member of the Board of Directors. The Board has accepted Mr. Maddaluna’s decision to continue serving as a director, and accordingly, Mr. Maddaluna will continue to serve as a Board member following the special meeting of stockholders and continue his membership of the Compensation Committee and Nominating Committee.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number		Description
10.1+		Salary Adjustment Agreement dated January 20 between the Company and Jeffrey A. Meckler
10.2+		Salary Adjustment Agreement dated January 20 between the Company and Michael J. Newman, Ph.D.
104		Cover Page Interactive Data File

+ Indicates a management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2026

	INDAPTUS THERAPEUTICS, INC.
	By:	/s/ Nir Sassi
	Name:	Nir Sassi
	Title:	Chief Financial Officer

FAQ

What executive compensation changes did Indaptus Therapeutics (INDP) disclose?

Indaptus Therapeutics disclosed that Co-Chief Executive Officer Jeffrey A. Meckler and Chief Science Officer Michael J. Newman, Ph.D. each entered into a Salary Adjustment Agreement. Effective January 15, 2026, their salaries were adjusted to $60,000 per annum for the remainder of the year, payable under the company’s standard payroll practices.

Which Indaptus Therapeutics executives are affected by the new Salary Adjustment Agreements?

The Salary Adjustment Agreements apply to Jeffrey A. Meckler, Co-Chief Executive Officer, and Michael J. Newman, Ph.D., Chief Science Officer. Each executive’s salary was set at $60,000 per year effective January 15, 2026 for the remainder of the year.

What change did Indaptus Therapeutics report regarding director Anthony Maddaluna?

Anthony Maddaluna, a member of the Board of Directors, had previously indicated he would resign effective as of the company’s next special meeting of stockholders. On January 20, 2026, he informed the company that he decided to rescind his resignation. The Board accepted this decision, and he will continue as a director.

Will Anthony Maddaluna remain on Indaptus Therapeutics’ board committees?

Yes. Indaptus Therapeutics stated that Anthony Maddaluna will continue serving on the Board of Directors and will also continue his membership on both the Compensation Committee and the Nominating Committee following the special meeting of stockholders.

Where can investors find the full salary adjustment agreements for INDP executives?

The salary adjustment agreements for Jeffrey A. Meckler and Michael J. Newman, Ph.D. are filed as exhibits to the report, identified as Exhibit 10.1 and Exhibit 10.2, and are incorporated by reference.

What form did Indaptus Therapeutics use to report these executive and board changes?

Indaptus Therapeutics reported these executive salary modifications and the director’s rescinded resignation in a Form 8-K under the item covering departures and appointments of directors and certain officers and compensatory arrangements.